文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

角质形成细胞生长因子治疗急性呼吸窘迫综合征(KARE):一项随机、双盲、安慰剂对照的2期试验

Keratinocyte growth factor for the treatment of the acute respiratory distress syndrome (KARE): a randomised, double-blind, placebo-controlled phase 2 trial.
PubMed 文献 · Lancet Respir Med · 2017-05-16
一句话结论在ARDS患者中,每日给予帕利夫明60 μg/kg最多6天未改善第7天氧合指数,且可能有害。

KARE是一项在英国两个ICU进行的随机、双盲、安慰剂对照2期试验,纳入符合美欧共识会议ARDS定义的60例患者,1:1随机接受重组人角质形成细胞生长因子(帕利夫明60 μg/kg)或安慰剂每日给药最多6天。主要终点第7天氧合指数两组无显著差异(KGF组均值62.3 vs 安慰剂组43.1,均差19.2,95%CI -5.6至44.0,P=0.13)。非预设终点中,KGF组无呼吸机天数更少(中位1天 vs 20天,差值-8天,95%CI -17至-2,P=0.0002)、幸存者机械通气时间更长(中位16天 vs 11天,差值6天,95%CI 2至14,P=0.002)、28天死亡风险比3.2(95%CI 1.0至10.7,P=0.054)、不良事件更多(14 vs 5次,OR 4.9,95%CI 1.3至20.3,P=0.008)。作者结论为KGF未改善ARDS的生理或临床结局,且可能对患者健康有害。

要点

  • ARDS患者每日给予帕利夫明60 μg/kg最多6天,第7天氧合指数与安慰剂无显著差异(均值62.3 vs 43.1,均差19.2,95%CI -5.6至44.0,P=0.13)。
  • KGF组无呼吸机天数中位1天 vs 安慰剂组20天(差值-8天,95%CI -17至-2,P=0.0002),为原文非预设终点。
  • KGF组28天死亡9例(31%)vs 安慰剂组3例(10%),风险比3.2(95%CI 1.0至10.7,P=0.054)。
  • KGF组不良事件14次 vs 安慰剂组5次(OR 4.9,95%CI 1.3至20.3,P=0.008);2次判定与KGF相关的不良事件为发热。
  • 作者结论:KGF未改善ARDS的生理或临床结局,且可能对患者健康有害。

适用人群与场景

  • 英国两个ICU中符合美欧共识会议ARDS定义的患者。
  • 随机按中心和是否需要血管加压药的严重脓毒症分层。

诊断标准与关键阈值

  • 纳入标准:符合美欧共识会议ARDS定义。

处置流程与药物剂量

  • 帕利夫明60 μg/kg每日给药,最多6天,与安慰剂(0.9%氯化钠溶液)对照,双盲设计。

研究设计与关键结果

  • 随机、双盲、分配隐藏、安慰剂对照2期试验,在英国两个ICU进行,60例患者随机(KGF组29例,安慰剂组31例),全部纳入主要终点分析。
  • 主要终点第7天氧合指数:KGF组均值62.3(SD 57.8)vs 安慰剂组43.1(SD 33.5),均差19.2(95%CI -5.6至44.0),P=0.13,无显著差异。
  • 非预设终点无呼吸机天数:KGF组中位1天(IQR 0至17)vs 安慰剂组20天(IQR 13至22),差值-8天(95%CI -17至-2),P=0.0002。
  • 非预设终点至第90天幸存者机械通气时间:KGF组中位16天(IQR 13至30)vs 安慰剂组11天(IQR 8至16),差值6天(95%CI 2至14),P=0.002。
  • 28天死亡:KGF组9例(31%)vs 安慰剂组3例(10%),风险比3.2(95%CI 1.0至10.7),P=0.054。
  • 不良事件:KGF组14次 vs 安慰剂组5次,OR 4.9(95%CI 1.3至20.3),P=0.008;判定与KGF相关的2次不良事件为发热。

证据类型、等级与局限

  • 证据类型:随机、双盲、安慰剂对照2期试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者结论:KGF未改善ARDS的生理或临床结局,且可能对患者健康有害。

指南或共识出处

  • KARE试验,注册号ISRCTN95690673。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Data from in-vitro, animal, and human lung injury models suggest that keratinocyte growth factor (KGF) might be beneficial in acute respiratory distress syndrome (ARDS). The objective of this trial was to investigate the effect of KGF in patients with ARDS.

METHODS: We did a double-blind, allocation concealed, randomised, placebo-controlled phase 2 trial in two intensive care units in the UK, involving patients fulfilling the American-European Consensus Conference Definition of ARDS. Patients were randomly assigned (1:1) by computer-generated randomisation schedule with variable block size stratified by site and presence of severe sepsis requiring vasopressors to receive either recombinant human KGF (palifermin 60 μg/kg) or placebo (0·9% sodium chloride solution) daily for a maximum of 6 days. Both patients and investigators were masked to treatment. The primary endpoint was oxygenation index (OI) at day 7. Analyses were by intention to treat. The trial is registered with International Standard Randomised Controlled Trial Registry, number ISRCTN95690673.

FINDINGS: Between Feb 23, 2011, and Feb 26, 2014, 368 patients were assessed for eligibility for inclusion in the trial. Of the 60 patients recruited, 29 patients were randomly assigned to receive KGF and 31 to placebo; all were included in the analysis of the primary outcome. There was no significant difference between the two groups in OI at day 7 (mean 62·3 [SD 57·8] in the KGF group, 43·1 [33·5] in the placebo group; mean difference 19·2, 95% CI -5·6 to 44·0, p=0·13). Of interest, although not defined as outcome measures a priori, the KGF group, compared with placebo, had fewer median ventilator-free days (1 day [IQR 0 to 17] in the KGF group vs 20 days [13-22] in the placebo group; difference -8 days, 95% CI -17 to -2; p=0·0002), a longer median duration of ventilation in survivors to day 90 (16 days [IQR 13-30] in the KGF group vs 11 days [8-16] in the placebo group; difference 6 days, 95% CI 2 to 14; p=0·002), and a higher mortality at 28 days (nine [31%] vs three [10%] deaths; risk ratio 3·2, 95% CI 1·0 to 10·7, p=0·054). Adverse events were more frequent in the KGF group than the placebo group (14 vs 5 events; odds ratio 4·9, 95% CI 1·3 to 20·3, p=0·008). The two adverse events assessed as related to KGF were due to pyrexia.

INTERPRETATION: KGF did not improve physiological or clinical outcomes in ARDS and might be harmful to patient health.

FUNDING: The Northern Ireland Public Health Agency Research and Development Division.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

参考来源

  1. McAuley DF, Cross LM, Hamid U, et al. Keratinocyte growth factor for the treatment of the acute respiratory distress syndrome (KARE): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Respir Med. 2017. PMID: 28526233. doi:10.1016/S2213-2600(17)30171-6

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。